MA53124B1 - Agents de dégradation sélectifs des récepteurs des oestrogènes - Google Patents

Agents de dégradation sélectifs des récepteurs des oestrogènes

Info

Publication number
MA53124B1
MA53124B1 MA53124A MA53124A MA53124B1 MA 53124 B1 MA53124 B1 MA 53124B1 MA 53124 A MA53124 A MA 53124A MA 53124 A MA53124 A MA 53124A MA 53124 B1 MA53124 B1 MA 53124B1
Authority
MA
Morocco
Prior art keywords
estrogen receptor
selective estrogen
receptor degraders
degraders
serd
Prior art date
Application number
MA53124A
Other languages
English (en)
Other versions
MA53124A (fr
Inventor
Jennifer Anne McMahon
Almudena Rubio
Jolie Anne Bastian
Jeffrey Daniel Cohen
Daniel Jon Sall
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53124(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53124A publication Critical patent/MA53124A/fr
Publication of MA53124B1 publication Critical patent/MA53124B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

L'invention concerne de nouveaux agents de dégradation sélectifs des récepteurs des oestrogènes (serd) selon la formule :, des sels pharmaceutiquement acceptables de ceux-ci, et des compositions pharmaceutiques de ceux-ci, formule dans laquelle l'un parmi r1 et r2 est indépendamment choisi parmi cl, f, -cf3 ou -ch3, et l'autre est l'hydrogène, et des procédés pour leur utilisation.
MA53124A 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes MA53124B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
PCT/US2019/041334 WO2020014435A1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes

Publications (2)

Publication Number Publication Date
MA53124A MA53124A (fr) 2021-05-19
MA53124B1 true MA53124B1 (fr) 2023-02-28

Family

ID=67470734

Family Applications (2)

Application Number Title Priority Date Filing Date
MA53124A MA53124B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes
MA53126A MA53126B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs du récepteur des oestrogènes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA53126A MA53126B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs du récepteur des oestrogènes

Country Status (36)

Country Link
US (4) US10654866B2 (fr)
EP (2) EP3820873B1 (fr)
JP (4) JP6995241B2 (fr)
KR (3) KR20230148386A (fr)
CN (2) CN112638916B (fr)
AR (1) AR115694A1 (fr)
AU (2) AU2019299947B2 (fr)
BR (2) BR112020025654A2 (fr)
CA (1) CA3105501C (fr)
CL (1) CL2021000045A1 (fr)
CO (1) CO2021000043A2 (fr)
CR (1) CR20210007A (fr)
DK (1) DK3820873T3 (fr)
EA (1) EA202092975A1 (fr)
EC (1) ECSP21001770A (fr)
ES (1) ES2933980T3 (fr)
FI (1) FI3820873T3 (fr)
HR (1) HRP20230009T1 (fr)
HU (1) HUE060963T2 (fr)
IL (3) IL280065B (fr)
JO (1) JOP20210005A1 (fr)
LT (1) LT3820873T (fr)
MA (2) MA53124B1 (fr)
MD (1) MD3820873T2 (fr)
MX (2) MX2021000375A (fr)
PE (1) PE20210400A1 (fr)
PH (1) PH12021550049A1 (fr)
PL (1) PL3820873T3 (fr)
PT (1) PT3820873T (fr)
RS (1) RS63809B1 (fr)
SA (1) SA521421008B1 (fr)
SG (1) SG11202100148TA (fr)
SI (1) SI3820873T1 (fr)
TW (1) TWI702219B (fr)
UA (1) UA127507C2 (fr)
WO (1) WO2020014435A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3355884T3 (pl) 2015-10-01 2021-11-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pirydo[3,4-b]indolowe leki antyestrogenowe
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
JOP20210004A1 (ar) * 2018-07-12 2021-01-10 Lilly Co Eli عوامل تحلّل مستقبلات الإستروجين الانتقائية
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TW202300492A (zh) * 2021-03-16 2023-01-01 美商美國禮來大藥廠 選擇性雌激素受體降解劑
AU2023216654A1 (en) * 2022-02-01 2024-07-11 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
WO2024083716A1 (fr) 2022-10-17 2024-04-25 Astrazeneca Ab Combinaisons d'un serd pour le traitement du cancer
WO2024097206A1 (fr) 2022-11-02 2024-05-10 Petra Pharma Corporation Inhibiteurs chroménones allostériques de la phosphoinositide 3-kinase (pi3k) pour le traitement d'une maladie
WO2024100236A1 (fr) 2022-11-11 2024-05-16 Astrazeneca Ab Polythérapies pour le traitement du cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395563B1 (fr) * 2001-05-22 2006-03-29 Eli Lilly And Company 1,2,3,4-tetrahydroquinoline 2-substituees et leurs derives, ainsi que leurs composition et leurs procedes
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
CA2482986A1 (fr) * 2002-04-19 2003-10-30 Signal Pharmaceuticals, Inc. Composes benzopyranone, compositions contenant ces composes et methodes de traitement associees
ATE476428T1 (de) * 2004-01-22 2010-08-15 Lilly Co Eli Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
BR112015030595A2 (pt) * 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
US9845291B2 (en) * 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
KR102559719B1 (ko) * 2014-12-18 2023-07-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
WO2018108954A1 (fr) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Procédé de préparation de 2-(3-(fluorométhyl)azétidin-1-yl)éthan-1-ol
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
JOP20210004A1 (ar) * 2018-07-12 2021-01-10 Lilly Co Eli عوامل تحلّل مستقبلات الإستروجين الانتقائية

Also Published As

Publication number Publication date
CN112638916A (zh) 2021-04-09
ES2933980T3 (es) 2023-02-15
RS63809B1 (sr) 2023-01-31
HUE060963T2 (hu) 2023-04-28
JP2022037102A (ja) 2022-03-08
JP2023081954A (ja) 2023-06-13
US20200017516A1 (en) 2020-01-16
EA202092975A1 (ru) 2021-04-14
UA127507C2 (uk) 2023-09-13
US10654866B2 (en) 2020-05-19
KR20230005404A (ko) 2023-01-09
AU2019299947A1 (en) 2021-01-07
US20230234960A1 (en) 2023-07-27
CL2021000045A1 (es) 2021-07-19
IL289871A (en) 2022-03-01
CA3105501A1 (fr) 2020-01-16
AU2022203969B2 (en) 2024-02-15
US11634426B2 (en) 2023-04-25
BR112020025654A2 (pt) 2021-04-06
KR20210019065A (ko) 2021-02-19
CO2021000043A2 (es) 2021-01-18
EP3820873A1 (fr) 2021-05-19
TW202019935A (zh) 2020-06-01
SG11202100148TA (en) 2021-02-25
EP4155310A1 (fr) 2023-03-29
HRP20230009T1 (hr) 2023-02-17
EP3820873B1 (fr) 2022-11-23
TWI702219B (zh) 2020-08-21
KR20230148386A (ko) 2023-10-24
JP7241211B2 (ja) 2023-03-16
MA53126B1 (fr) 2023-02-28
DK3820873T3 (da) 2022-12-12
CN112638916B (zh) 2023-09-12
SI3820873T1 (sl) 2023-02-28
IL295598B1 (en) 2023-05-01
KR102550538B1 (ko) 2023-07-04
CN117379428A (zh) 2024-01-12
WO2020014435A1 (fr) 2020-01-16
CA3105501C (fr) 2023-10-31
IL280065A (en) 2021-03-01
SA521421008B1 (ar) 2022-10-30
MD3820873T2 (ro) 2023-05-31
ECSP21001770A (es) 2021-02-26
IL289871B2 (en) 2023-02-01
IL295598B2 (en) 2023-09-01
JP2022050591A (ja) 2022-03-30
AR115694A1 (es) 2021-02-17
MX2021000375A (es) 2021-05-27
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
PT3820873T (pt) 2022-12-23
PE20210400A1 (es) 2021-03-02
PH12021550049A1 (en) 2021-09-20
JP6995241B2 (ja) 2022-01-14
FI3820873T3 (fi) 2023-03-02
JOP20210005A1 (ar) 2021-01-10
US20200347073A1 (en) 2020-11-05
MA53126A (fr) 2021-05-19
BR122023025061A2 (pt) 2024-02-20
CR20210007A (es) 2021-02-08
IL295598A (en) 2022-10-01
PL3820873T3 (pl) 2023-02-13
JP2021530484A (ja) 2021-11-11
MA53124A (fr) 2021-05-19
US11117902B2 (en) 2021-09-14
AU2022203969A1 (en) 2022-06-30
US20210403480A1 (en) 2021-12-30
KR102589886B1 (ko) 2023-10-17
LT3820873T (lt) 2023-01-10
AU2019299947B2 (en) 2022-03-17
IL280065B (en) 2022-04-01
IL289871B (en) 2022-10-01
JP7009672B1 (ja) 2022-01-25

Similar Documents

Publication Publication Date Title
MA53124B1 (fr) Agents de dégradation sélectifs des récepteurs des oestrogènes
MA31419B1 (fr) Derives de pyridine
BR112020001825A2 (pt) compostos e métodos para a degradação direcionada de receptor de androgênio
MA29791B1 (fr) Composes therapeutiques.
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA39043A1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
MA31766B1 (fr) Composés organiques
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
EP2202222A3 (fr) Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
EA200700099A1 (ru) Производные пиридина
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
HUP0300867A2 (hu) Aril-szubsztituált pirazolok, triazolok és tetrazolok és alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
MA30999B1 (fr) Composés.
GEP20094727B (en) Oxyindole derivatives as 5ht4 receptor agonists
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA49127B1 (fr) Dérivés d'indole n-substitués
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA34760B1 (fr) Composés et leurs utilisation
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
MA45888A1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA41494B1 (fr) Composés benzoxaborole substitués en position 4 et utilisations associées